Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
Multi-Center Study Using Allogeneic Stem Cell Transplantation Following Reduced Intensity Chemotherapy in Patients With Hemoglobinopathies
Sponsor: Beth Israel Deaconess Medical Center
A PHASE2 clinical study on Hemoglobinopathies and Sickle Cell Disease, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 9 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Mar 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- Emory University
- Feist-Weiller Cancer Center at Louisiana State University Health Sciences
- Massachusetts General Hospital
- Ohio State University
For direct contact, visit the study record on ClinicalTrials.gov .